Psilocybin as a novel treatment for chronic pain
Tate Askey, Reena Lasrado, Maria Maiarù, Gary J. Stephens
British Journal of Pharmacology November 29, 2024 DOI: 10.1111/bph.17420 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Topics | Neuroplasticity Psilocybin Serotonin |
| Keywords | Neuropathic pain Chronic pain Nociception Hallucinogen |
| Citations | 13 |
| Key findings | Psilocybin shows potential as an anti-nociceptive agent for chronic pain through serotonergic and neuroplastic mechanisms, but further research is needed. |
Abstract
Abstract Psychedelic drugs are under active consideration for clinical use and have generated significant interest for their potential as anti‐nociceptive treatments for chronic pain, and for addressing conditions like depression, frequently co‐morbid with pain. This review primarily explores the utility of preclinical animal models in investigating the potential of psilocybin as an anti‐nociceptive agent. Initial studies involving psilocybin in animal models of neuropathic and inflammatory pain are summarised, alongside areas where further research is needed. The potential mechanisms of action, including targeting serotonergic pathways through the activation of 5‐HT 2A receptors at both spinal and central levels, as well as neuroplastic actions that improve functional connectivity in brain regions involved in chronic pain, are considered. Current clinical aspects and the translational potential of psilocybin from animal models to chronic pain patients are reviewed. Also discussed is psilocybin's profile as an ideal anti‐nociceptive agent, with a wide range of effects against chronic pain and its associated inflammatory or emotional components.